Subscribe To
MIST / Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023
Content Topics
Milestone
Pharmaceuticals
Potential
Submission
Etripamil
Pharmaceuticals
Catalyst
Mid 2023
Stock
MIST
MIST News
By Seeking Alpha
May 22, 2023
Milestone Pharmaceuticals: Worthy Of A Dart Throw
Today, we take a deeper look at Milestone Pharmaceuticals Inc. for the first time on Seeking Alpha. The company's primary drug candidate has a novel d more_horizontal
By Zacks Investment Research
January 16, 2023
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This more_horizontal
By Zacks Investment Research
December 13, 2022
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
The heavy selling pressure might have exhausted for Milestone Pharmaceuticals (MIST) as it is technically in oversold territory now. In addition to th more_horizontal
By Seeking Alpha
November 5, 2022
Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023
Etripamil succeeded in phase 3 RAPID study, Milestone in talks with FDA to possibly file an NDA for this drug in treating PSVT patients by mid-2023. I more_horizontal